Vincent Piguet

Vincent Piguet

Auto-generated profile, based on publicly available information

Vincent Piguet

Division of Dermatology, Department of Medicine, Women’s College Hospitals, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2007 in Nature Medicine
Verified
Journal Article
Closed access
LWLot de Witte
Lot de Witte
ANAlexey Nabatov
Alexey Nabatov
MPMarjorie Pion
Marjorie Pion
DFDonna Fluitsma
Donna Fluitsma
MJMarein A W P de Jong
Marein A W P de Jong
TGTeunis B H Geijtenbeek
Teunis B H Geijtenbeek

1 March 2002 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AEAnneke Engering
Anneke Engering
TGTeunis B. H. Geijtenbeek
Teunis B. H. Geijtenbeek
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
MWMietske Wijers
Mietske Wijers
ELEllis van Liempt
Ellis van Liempt
YKYvette van Kooyk
Yvette van Kooyk
Dendritic cells (DCs) capture Ags or viruses in peripheral tissue to transport them to lymphoid organs to induce cellular T cell responses. Recently, a DC-specific C-type lectin was identified, DC-specific ICAM-grabbing non-integrin (DC-SIGN), that functions as cell adhesion receptor mediating both DC migration and T cell activation. DC-SIGN also functions as an HIV-1R that captures HIVgp120 and facilitates DC-induced HIV transmission of T cells. Internalization motifs in the cytoplasmic tail of DC-SIGN hint to a function of DC-SIGN as endocytic receptor. In this study we demonstrate that on DCs DC-SIGN is rapidly internalized upon binding of soluble ligand. Mutating a putative internalization motif in the cytoplasmic tail reduces ligand-induced internalization. Detailed analysis using ratio fluorescence imaging and electron microscopy showed that DC-SIGN-ligand complexes are targeted to late endosomes/lysosomes. Moreover, ligands internalized by DC-SIGN are efficiently processed and presented to CD4+ T cells. The distinct pattern of expression of C-type lectins on DCs in situ and their nonoverlapping Ag recognition profile hint to selective functions of these receptors to allow a DC to recognize a wide variety of Ags and to process these to induce T cell activation. These data point to a novel function of the adhesion receptor DC-SIGN as an efficient DC-specific Ag receptor that can be used as a target to induce viral and antitumor immunity.

3 April 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
BSBarbara Stecca
Barbara Stecca
CMChristophe Mas
Christophe Mas
VCVirginie Clement
Virginie Clement
MZMarie Zbinden
Marie Zbinden
RCRafael Correa-Rocha
Rafael Correa-Rocha
AAAriel Ruiz i Altaba
Ariel Ruiz i Altaba
Melanoma is one of the most aggressive cancers, and its incidence is increasing. These tumors derive from the melanocyte lineage and remain incurable after metastasis. Here we report that SONIC HEDGEHOG (SHH)-GLI signaling is active in the matrix of human hair follicles, and that it is required for the normal proliferation of human melanocytes in culture. SHH-GLI signaling also regulates the proliferation and survival of human melanomas: the growth, recurrence, and metastasis of melanoma xenografts in mice are prevented by local or systemic interference of HH-GLI function. Moreover, we show that oncogenic RAS-induced melanomas in transgenic mice express Gli1 and require Hh-Gli signaling in vitro and in vivo . Finally, we provide evidence that endogenous RAS-MEK and AKT signaling regulate the nuclear localization and transcriptional activity of GLI1 in melanoma and other cancer cells. Our data uncover an unsuspected role of HH-GLI signaling in melanocytes and melanomas, demonstrate a role for this pathway in RAS-induced tumors, suggest a general integration of the RAS/AKT and HH-GLI pathways, and open a therapeutic approach for human melanomas.

4 September 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
BMBastien Mangeat
Bastien Mangeat
GGGustavo Gers-Huber
Gustavo Gers-Huber
MLMartin Lehmann
Martin Lehmann
MZMadeleine Zufferey
Madeleine Zufferey
JLJeremy Luban
Jeremy Luban
VPVincent Piguet
Vincent Piguet
Host cells impose a broad range of obstacles to the replication of retroviruses. Tetherin (also known as CD317, BST-2 or HM1.24) impedes viral release by retaining newly budded HIV-1 virions on the surface of cells. HIV-1 Vpu efficiently counteracts this restriction. Here, we show that HIV-1 Vpu induces the depletion of tetherin from cells. We demonstrate that this phenomenon correlates with the ability of Vpu to counteract the antiviral activity of both overexpressed and interferon-induced endogenous tetherin. In addition, we show that Vpu co-immunoprecipitates with tetherin and β-TrCP in a tri-molecular complex. This interaction leads to Vpu-mediated proteasomal degradation of tetherin in a β-TrCP2-dependent manner. Accordingly, in conditions where Vpu-β-TrCP2-tetherin interplay was not operative, including cells stably knocked down for β-TrCP2 expression or cells expressing a dominant negative form of β-TrCP, the ability of Vpu to antagonize the antiviral activity of tetherin was severely impaired. Nevertheless, tetherin degradation did not account for the totality of Vpu-mediated counteraction against the antiviral factor, as binding of Vpu to tetherin was sufficient for a partial relief of the restriction. Finally, we show that the mechanism used by Vpu to induce tetherin depletion implicates the cellular ER-associated degradation (ERAD) pathway, which mediates the dislocation of ER membrane proteins into the cytosol for subsequent proteasomal degradation. In conclusion, we show that Vpu interacts with tetherin to direct its β-TrCP2-dependent proteasomal degradation, thereby alleviating the blockade to the release of infectious virions. Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication. To efficiently replicate in cells, HIV-1 needs to inactivate a number of intracellular host defenses. One such antiviral mechanism is provided by the newly identified tetherin protein. This factor blocks viral production by impeding the release of newly generated HIV-1 particles from the surface of cells. HIV-1 possesses the Vpu protein, which efficiently counteracts this blockade. Here we reveal that HIV-1 Vpu interacts with tetherin and leads to its depletion from cells, possibly through multiple mechanisms, including proteasomal degradation. In order to eliminate tetherin, Vpu hijacks a cellular component, named β-TrCP2, which is normally used by human cells to induce degradation of certain proteins. Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication.

1 May 2010 in Immunity
Verified
Journal Article
Closed access
FBFabien P. Blanchet
Fabien P. Blanchet
AMArnaud Moris
Arnaud Moris
DNDamjan S. Nikolic
Damjan S. Nikolic
MLMartin Lehmann
Martin Lehmann
SCSylvain Cardinaud
Sylvain Cardinaud
VPVincent Piguet
Vincent Piguet

9 February 2000 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
VPVincent Piguet
Vincent Piguet
LWLei Wan
Lei Wan
CBChristelle Borel
Christelle Borel
AMAram Mangasarian
Aram Mangasarian
NDNicolas Demaurex
Nicolas Demaurex
DTDidier Trono
Didier Trono